Table 1.

Characteristics of HPV VLP Vaccines

Manufacturer	Merck™ (Gardasil®, 4vHPV)	GlaxoSmithKline™ (Cervarix®, 2vHPV)	Merck™ (Gardasil® 9, 9vHPV)
L1 VLP types	6, 11, 16 and 18	16 and 18	6, 11, 16, 18, 31, 33, 45, 52, and 58
Dose	20/40/40/20 µg	20/20 µg	30/40/60/40/ 20/20/20/20/20
Producer cells	Saccharomyces cerevisiae (baker’s yeast) expressing L1	Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus	Saccharomyces cerevisiae (baker’s yeast) expressing L1
Adjuvant	225 µg aluminium hydroxyphosphate sulfate	500 µg aluminium hydroxide, 50 µg 3-O-deacylated-4’-monophosphoryl lipid A	500 µg aluminium hydroxyphosphate sulfate
*Vaccination schedule	0, 2 and 6 months	0, 1 and 6 months	0, 2 and 6 months

HPV, Human papillomavirus; VLP, Virus-like particles;

^*WHO recommends two-dose schedule for girls <15 years old, provided the second dose is given at least six months apart